PTGER2

Prostaglandin E2 receptor EP2 subtype · P43116 · PTGER2 on Sugi Atlas →

91,188 patent compounds predicted against PTGER2, 49,386 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL533125	1.00	20/20
SCHEMBL533132	1.00	20/20
SCHEMBL533135	1.00	20/20
SCHEMBL533198	1.00	20/20
SCHEMBL533241	1.00	20/20
Omidenepag (SCHEMBL533245)	1.00	20/20
Hydrochloric Acid (SCHEMBL533332)	1.00	20/20
SCHEMBL533390	1.00	20/20
Hydrochloric Acid (SCHEMBL533403)	1.00	20/20
Hydrochloric Acid (SCHEMBL533413)	1.00	20/20
Omidenepag (SCHEMBL533632)	1.00	20/20
Hydrochloric Acid (SCHEMBL533771)	1.00	20/20
Hydrochloric Acid (SCHEMBL533836)	1.00	20/20
SCHEMBL534069	1.00	20/20
SCHEMBL534218	1.00	20/20
SCHEMBL534263	1.00	20/20
Hydrochloric Acid (SCHEMBL534297)	1.00	20/20
Hydrochloric Acid (SCHEMBL534379)	1.00	20/20
SCHEMBL533104	0.89	20/20
SCHEMBL533396	0.81	20/20

Clinical trials — most relevant to PTGER2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes	PHASE4	UNKNOWN
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA	PHASE2/PHASE3	COMPLETED
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs	PHASE3	COMPLETED
Addition of Aspirin to Standard of Care in Oral Cancer	PHASE2/PHASE3	COMPLETED
Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19	PHASE3	COMPLETED
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages	PHASE2/PHASE3	UNKNOWN
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial	PHASE3	UNKNOWN
Ibuprofen in Sepsis Study	PHASE3	COMPLETED
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
HTL0039732 in Participants With Advanced Solid Tumours	PHASE1/PHASE2	RECRUITING
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention	PHASE2	COMPLETED
Celebrex for Pain Relief After Oral Surgery	PHASE2	COMPLETED
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Adjunctive Celecoxib in Childhood-onset OCD Study	PHASE2	UNKNOWN
Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury	PHASE2	WITHDRAWN
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma	PHASE2	COMPLETED
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine	PHASE2	WITHDRAWN
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors	PHASE1	COMPLETED
Pathways of Eicosanoid Metabolism	EARLY_PHASE1	ENROLLING_BY_INVITATION
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN
PGE2/IL-22 Pathway in Various Forms of Eczema	nan	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer	nan	UNKNOWN
A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS	nan	UNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTGER2 binder may also engage these)

Protein	Name	Similarity
Q62053	—	1.000	Q62053 →
Q62928	—	0.999	Q62928 →
Q9XT82	—	0.998	Q9XT82 →
O35932	—	0.990	O35932 →
Q9R261	—	0.990	Q9R261 →
A5D7K8	—	0.987	A5D7K8 →
P70263	—	0.986	P70263 →
P30987	—	0.985	P30987 →
P30557	—	0.984	P30557 →
P34980	—	0.983	P34980 →
Q95125	—	0.981	Q95125 →
P79393	—	0.981	P79393 →
P34978	—	0.980	P34978 →
PTGER3	Prostaglandin E2 receptor EP3 subtype	0.979	landscape →
P50131	—	0.979	P50131 →
P46069	—	0.978	P46069 →
P47752	—	0.977	P47752 →
PTGDR	Prostaglandin D2 receptor	0.976	landscape →
P43253	—	0.976	P43253 →
PTGIR	Prostacyclin receptor	0.975	landscape →
TBXA2R	Thromboxane A2 receptor	0.974	landscape →
P56486	—	0.973	P56486 →
P43252	—	0.973	P43252 →
P52592	—	0.972	P52592 →
P43117	—	0.971	P43117 →
P34979	—	0.970	P34979 →
S1PR2	Sphingosine 1-phosphate receptor 2	0.968	landscape →
P35375	—	0.968	P35375 →
P43118	—	0.968	P43118 →
P70597	—	0.967	P70597 →